A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1

被引：0

作者：

Oh, D-Y. ^{[1
]}

Chen, L-T. ^{[2
]}

He, A. R. ^{[3
]}

Okusaka, T. ^{[4
]}

Qin, S. ^{[5
]}

Chin, S. ^{[6
]}

Rokutanda, N. ^{[6
]}

Uchinda, H. ^{[7
]}

Vogel, A. ^{[8
]}

Valle, J. W. ^{[9
]}

Kim, H. ^{[7
]}

机构：

[1] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea

[2] Natl Inst Canc Res, Natl Hlth Res Inst, Tainan, Taiwan

[3] Georgetown Univ, Med Ctr, Div Hematol & Oncol, Washington, DC 20007 USA

[4] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan

[5] Peoples Liberat Army, Ctr Canc, Med Oncol, Nanjing, Jiangsu, Peoples R China

[6] AstraZeneca, Oncol, Gaithersburg, MD USA

[7] AstraZeneca KK, R&D, TA Div, Med Sci Dept Oncol, Osaka, Japan

[8] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany

[9] Univ Manchester, Christie NHS Fdn Trust, Inst Canc Sci, Med Oncol, Manchester, Lancs, England

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

831TiP

引用

页码：319 / 319

页数：1

共 50 条

[21] Impact of mutation status on efficacy outcomes in TOPAZ-1: A Phase 3 study of Durvalumab (D) or Placebo (PBO) plus Gemcitabine and Cisplatin ( plus GC) in advanced Biliary Tract Cancer (BTC)
Vogel, A.
Valle, J.
Qin, S.
Antonuzo, L.
Tougeron, D.
Lee, C. -K.
Tan, B.
Ikeda, M.
Guthrie, V.
McCoon, P.
Lee, Y.
Rokutanda, N.
Watras, M.
Cohen, G.
Oh, D. -Y.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 63 - 64
[22] Impact of mutation status on efficacy outcomes in TOPAZ-1: A Phase 3 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)
Vogel, Arndt
Valle, Juan
Qin, Shukui
Antonuzzo, Lorenzo
Tougeron, David
Lee, Choongkun
Tan, Benjamin
Ikeda, Masafumi
Guthrie, Violeta
Mccoon, Patricia
Lee, Young
Rokutanda, Nana
Zotkiewicz, Magdalena
Cohen, Gordon
Oh, Do-Youn
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 68 - 68
[23] Gemcitabine/cisplatin plus bevacizumab or placebo in advanced malignant mesothelioma: A multi-center, double-blind, placebo-controlled, randomized phase III trial
Kindler, H
Lu, C
Gandara, D
Stevenson, J
Krug, L
Janne, P
Gitlitz, B
Karrison, T
Stadler, W
Vokes, E
LUNG CANCER, 2005, 49 : S28 - S29
[24] Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)
Antonuzzo, L.
Takahashi, H.
Park, J. O.
Sookprasert, A.
Gillmore, R.
Yang, S-S.
Cundom, J. E.
Petrova, M.
Vaccaro, G. M.
Holmblad, M.
Xiong, J.
Heider, K.
Rokutanda, N.
Oh, D-Y.
ANNALS OF ONCOLOGY, 2022, 33 : S1470 - S1470
[25] Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)
Antonuzzo, L.
Takahashi, H.
Park, J. O.
Sookprasert, A.
Gillmore, R.
Yang, S-S.
Cundom, J. E.
Petrova, M.
Vaccaro, G. M.
Holmblad, M.
Xiong, J.
Heider, K.
Rokutanda, N.
Oh, D-Y.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S566 - S567
[26] Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma
Kindler, Hedy L.
Karrison, Theodore G.
Gandara, David R.
Lu, Charles
Krug, Lee M.
Stevenson, James P.
Jaenne, Pasi A.
Quinn, David I.
Koczywas, Marianna N.
Brahmer, Julie R.
Albain, Kathy S.
Taber, David A.
Armato, Samuel G., III
Vogelzang, Nicholas J.
Chen, Helen X.
Stadler, Walter M.
Vokes, Everett E.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) : 2509 - 2515
[27] Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer
Oh, Do-Youn
Qin, Shukui
Antonuzzo, Lorenzo
Tougeron, David
Lee, Choong-kun
Tan, Benjamin R.
Ikeda, Masafumi
Wang, Julie
Lin, Hung-Ying
Lee, Young S.
Mccoon, Patricia
Valle, Juan W.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 625 - 625
[28] BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
Goncalves, A.
Gilabert, M.
Francois, E.
Dahan, L.
Perrier, H.
Lamy, R.
Re, D.
Largillier, R.
Gasmi, M.
Tchiknavorian, X.
Esterni, B.
Genre, D.
Moureau-Zabotto, L.
Giovannini, M.
Seitz, J-F.
Delpero, J-R.
Turrini, O.
Viens, P.
Raoul, J-L.
ANNALS OF ONCOLOGY, 2012, 23 (11) : 2799 - 2805
[29] Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
Moehler, M.
Maderer, A.
Schimanski, C.
Kanzler, S.
Denzer, U.
Kolligs, F. T.
Ebert, M. P.
Distelrath, A.
Geissler, M.
Trojan, J.
Schuetz, M.
Berie, L.
Sauvigny, C.
Lammert, F.
Lohse, A.
Dollinger, M. M.
Lindig, U.
Duerr, E. M.
Lubomierski, N.
Zimmermann, S.
Wachtlin, D.
Kaiser, A. -K.
Schadmand-Fischer, S.
Galle, P. R.
Woerns, M.
EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3125 - 3135
[30] Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase 3 TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)
Koenig, A.
Antonuzzo, L.
Takahashi, H.
Park, J. O.
Sookprasert, A.
Gillmore, R.
Yang, S. -S.
Cundom, J.
Petrova, M.
Vaccaro, G.
Holmblad, M.
Xiong, J.
Heider, K.
Rokutanda, N.
Oh, D. -Y.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 60 - 60

← 1 2 3 4 5 →